Caroline Palomeque
Stock Analyst at Maxim Group
(1.24)
# 3,710
Out of 5,126 analysts
10
Total ratings
44.44%
Success rate
-2.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DARE Daré Bioscience | Upgrades: Buy | $8 | $1.69 | +373.37% | 3 | Sep 4, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $59 | $37.27 | +58.30% | 1 | Sep 7, 2023 | |
| KRYS Krystal Biotech | Initiates: Buy | $154 | $272.74 | -43.54% | 1 | Sep 7, 2023 | |
| HALO Halozyme Therapeutics | Reinstates: Buy | $58 | $81.23 | -28.60% | 1 | Mar 27, 2023 | |
| ASND Ascendis Pharma | Assumes: Buy | $166 | $222.15 | -25.28% | 1 | Aug 30, 2022 | |
| DNLI Denali Therapeutics | Initiates: Buy | $39 | $21.08 | +85.01% | 1 | Jun 23, 2022 | |
| RGNX REGENXBIO | Initiates: Buy | $61 | $10.33 | +490.51% | 1 | Jun 23, 2022 | |
| AVXL Anavex Life Sciences | Initiates: Buy | $40 | $4.10 | +875.61% | 1 | Jun 23, 2022 |
Daré Bioscience
Sep 4, 2025
Upgrades: Buy
Price Target: $8
Current: $1.69
Upside: +373.37%
Harmony Biosciences Holdings
Sep 7, 2023
Initiates: Buy
Price Target: $59
Current: $37.27
Upside: +58.30%
Krystal Biotech
Sep 7, 2023
Initiates: Buy
Price Target: $154
Current: $272.74
Upside: -43.54%
Halozyme Therapeutics
Mar 27, 2023
Reinstates: Buy
Price Target: $58
Current: $81.23
Upside: -28.60%
Ascendis Pharma
Aug 30, 2022
Assumes: Buy
Price Target: $166
Current: $222.15
Upside: -25.28%
Denali Therapeutics
Jun 23, 2022
Initiates: Buy
Price Target: $39
Current: $21.08
Upside: +85.01%
REGENXBIO
Jun 23, 2022
Initiates: Buy
Price Target: $61
Current: $10.33
Upside: +490.51%
Anavex Life Sciences
Jun 23, 2022
Initiates: Buy
Price Target: $40
Current: $4.10
Upside: +875.61%